Mechanisms Underlying Impaired Diabetic Wound Healing

Mechanisms Underlying Impaired Wound Healing

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00777712

Acronym

WoundVAC

Enrollment

250

Registered

2008-10-22

Start date

2008-09-01

Completion date

2030-12-31

Last updated

2026-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-healing Wound

Keywords

Wound healing, diabetes, inflammatory cell, monocyte, leukocyte, macrophage

Brief summary

The overall aim of this research is to utilize wound derived inflammatory cells from diabetic versus non diabetic human chronic wounds to understand mechanisms that are responsible for disregulated inflammation in individuals with diabetes. Biology of normal (peripheral blood derived cells) versus wound derived cells will also be studied.

Detailed description

Specific aims: 1. To study biology of wound derived inflammatory cells and fluid from diabetic versus non diabetic wounds. 2. To characterize mechanisms that are responsible for dysregulated wound inflammatory cell function in individuals with diabetes. 3. To characterize differences in the biology of normal peripheral blood derived cells versus wound derived cells. The long-term goal of this study is to determine the molecular mechanisms underlying impaired wound healing in diabetics.

Interventions

OTHERBlood draw

Blood will be drawn from subjects once and VAC sponge will be collected (which is normally discarded material per standard of care).

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

21 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Ages 21-80 * Chronic Wound (present \>4 weeks) * Diabetic \& Non-diabetic * Adult surgical wounds

Exclusion criteria

* Inability to consent * Pregnant women * Therapeutically immunocompromised * Individuals defined in 45 CFR 46 Subparts B,C, and D, nor from any other population considered vulnerable 2.9

Design outcomes

Primary

Measure	Time frame	Description
Wound healing	Week 16	Wound healing status

Secondary

Measure	Time frame	Description
Infection status	week 0	CFU analysis of the wound fluid

Countries

United States

Contacts

CONTACTPiya Das Ghatak, PhD, MS

pid12@pitt.edu412-648-8297

CONTACTUrmila Gnyawali

USG2@pitt.edu4126240422

PRINCIPAL_INVESTIGATORSashwati Roy, Ph.D.

University of Pittsburgh

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 6, 2026